Financials and Corporate

Innate Pharma releases its total number of shares outstanding as well as its voting rights as at April 30, 2010: Total number of shares outstanding:37,686,794 Total number of theoretical voting rights...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces a turnover of 0.1 million euros (105 thousand euros) for the first quarter of 2010, compared with 2.5 million euros (2,488 thousand euros)...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that the French version of the 2009 Reference Document, including the Annual Financial Report, as well as the 2009 Annual Report of the...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on May 25, 2010, at 10 am in its headquarters, 117 avenue de Luminy, F-13009 Marseille...

Innate Pharma SA has released the total number of shares outstanding and voting rights, as of March 31, 2010

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces its participation to the following analyst and investor conferences in the coming weeks: CF&B Smallcap Event, April...

Progress of clinical portfolio and strenghtnening of cash position. Innate Pharma reports today its consolidated financial results for the year ending December 31, 2009. Unaudited consolidated...

(IFRS unaudited provisional data) Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) announces an operating revenue of 7.7 million euros for the year 2009. Turnover for the year...

Following the capital increase reserved to categories of investors executed in December 2009 and pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the...

Under the liquidity contract entrusted by Innate Pharma to Natixis Securities, the following assets appeared on the liquidity account as at December 31, 2009: 69,741 shares of Innate Pharma, and 121...